🇺🇸 FDA
Patent

US 9260726

Targeted integration and expression on exogenous nucleic acid sequences

granted A61KA61K48/0008A61K48/005

Quick answer

US patent 9260726 (Targeted integration and expression on exogenous nucleic acid sequences) held by Sangamo Biosciences, Inc. expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Biosciences, Inc.
Grant date
Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K48/0008, A61K48/005, A61K48/0058